Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 109.74 -2.27 (-2.03%) Market Cap: 6.92 Bil Enterprise Value: 11.03 Bil PE Ratio: 22.63 PB Ratio: 1.87 GF Score: 78/100

Jazz Pharmaceuticals PLC at Morgan Stanley Healthcare Conference Transcript

Sep 09, 2019 / 12:45PM GMT
Release Date Price: $125.29 (-0.93%)
David Reed Risinger
Morgan Stanley, Research Division - MD in Equity Research and United States Pharmaceuticals Analyst

Okay. So why don't I kick it off here? Thanks, everyone, for joining. It's very much my pleasure to introduce Jazz Pharmaceuticals. So Bruce Cozadd is the company's Chairman and CEO. He originally cofounded Jazz in 2003 and has served as Chairman and CEO since 2009. So we're fortunate to have you here with us, Bruce.

Questions & Answers

David Reed Risinger
Morgan Stanley, Research Division - MD in Equity Research and United States Pharmaceuticals Analyst

I thought it would be great to just have you start off talking a little bit about the vision that you have for Jazz and how you are acting on that vision and how you plan to execute in coming years.

Bruce C. Cozadd
Jazz Pharmaceuticals plc - Co-Founder, Chairman & CEO

Great. And thanks, Dave, for having us here at the conference. I will say before I start, I'll make forward-looking statements. Please see our SEC filings for risk

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot